Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil ... and helped build a case against the pharmaceutical industry before judges ...

Japanese pharmaceutical company Takeda inaugurated its first Innovation Capability Centre (ICC) in Bengaluru, marking its debut in Asia. The ICC aims to employ 750 professionals, including software ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

A golden chainsaw, representing Milei's economic plan in Argentina. President Javier Milei has managed to reignite his romance with Argentine society. Despite being elected with minimal ...

Award-winning star has released the visuals for 'Ecstacy' off his fourth album 'Adedamola'. Fireboy shares cinematic visuals for 'Ecstacy' featuring Seun Kuti The music video was released on ...

The growing investment in India's CDMO sector indicates confidence in India’s pharmaceutical sector and its potential - A detailed analysis. With the U.S. increasingly adopting an anti-China ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s ... aims to compete in a market now dominated by big pharma. As such, analysts have ...

Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.